HeartCore Enterprises, Inc. (Nasdaq: HTCR) has released its financial results for the first quarter of 2023, demonstrating remarkable growth in revenues. The company reported a substantial increase of 284% year-over-year, reaching $8.7 million in revenue. This exceptional growth can primarily be attributed to the expansion of the Go IPO business. Notably, the revenue generated in Q1 2023 nearly surpassed the company's total revenue for the entire year of 2022. Furthermore, the net income for Q1 2023 also exceeded the net income for the entirety of 2022.

In pre-market, shares of $HTCR were trading at $2.06, reflecting a substantial increase of $0.78 or 60.93%.

In other news, CohBar, Inc. (Nasdaq: CWBR) and Morphogenesis, Inc. have announced their entry into a definitive agreement for an all-stock transaction. This transaction will lead to the formation of a new company that combines the expertise and resources of both entities. Operating under the name "TuHURA Biosciences, Inc.," the newly formed company will focus on advancing Morphogenesis' two technologies designed to overcome the significant challenges hindering the effectiveness of current immunotherapies in cancer treatment. 

Following the announcement of the agreement, $CWBR experienced a notable surge in pre-market trading, with shares priced at $3.18, reflecting a substantial increase of $1.63 or 105.1613%.

Additionally, ResMed Inc. (NYSE: RMD) received positive attention from UBS, as it was initiated with a Buy rating and assigned a price target of $290. This positive endorsement by UBS indicates optimism in the company's future prospects.

$RMD is currently trading at $226.00 in pre-market, reflecting a modest increase of $0.54 or 0.24%.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)